PROM2 overexpression resulted in much shorter overall survival and disease-free survival times in pancreatic cancer patients who were treated with gemcitabine chemotherapy (P < 0.001; P < 0.001; n = 81, Fig. 2a, b, Supplementary Table S3). This evidence concerns the gene PROM2 and familial pancreatic carcinoma.